Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "Epidermal Growth Factor Receptor"

HUTCHMED, AstraZeneca Submit US NDA for Orpathys-Tagrisso Combination

AstraZeneca submits a US FDA NDA for Orpathys plus Tagrisso in MET-driven NSCLC following EGFR-TKI progression, supported by positive Phase 3 SAFFRON PFS and OS results.

Epidermal Growth Factor Receptor | 01/10/2026 | By News Bureau | 100

Johnson & Johnson Secures FDA Approval for Monthly RYBREVANT FASPRO Dosing in EGFR-Mutated Lung Cancer

Simplified once-monthly schedule for RYBREVANT FASPRO matches bi-weekly efficacy, reduces clinic visits and maintains a strong safety profile.

Epidermal Growth Factor Receptor | 18/02/2026 | By News Bureau | 165

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members